Ovarian Rejuvenation Therapies: Current Evidence

Abstract

Ovarian rejuvenation therapies represent a novel frontier in reproductive medicine, aiming to restore ovarian function in women with diminished ovarian reserve, premature ovarian insufficiency (POI), or age-related infertility. This review synthesizes the most recent evidence regarding the epidemiology, pathophysiology, clinical features, diagnostic pathways, and the evolving landscape of treatment and management, with a focus on mechanism-based interventions. Emerging therapies such as platelet-rich plasma (PRP), stem cell transplantation, and molecular signaling modulation are critically examined in the context of current clinical guidelines and practical application. The review provides a comprehensive analysis for clinicians seeking to integrate ovarian rejuvenation approaches into evidence-based practice.

Introduction

Ovarian aging and functional decline constitute significant challenges in reproductive medicine, especially as increasing numbers of women delay childbearing. Diminished ovarian reserve (DOR), POI, and the progressive reduction in both oocyte quantity and quality are major contributors to infertility, with limited conventional therapeutic options. Ovarian rejuvenation therapies have emerged as promising modalities, seeking not merely to supplement, but to restore ovarian function at a cellular and molecular level. This review explores the scientific rationale, clinical data, and current recommendations surrounding these interventions.

Epidemiology / Disease Burden

DOR affects approximately 10% of women seeking fertility treatment, while POI presents in 1–2% of women under 40 years of age. The global trend of delayed parenthood has amplified the prevalence and impact of age-related ovarian failure. Infertility secondary to ovarian insufficiency imposes significant psychosocial and economic burdens on affected women and healthcare systems, emphasizing the need for innovative therapeutic strategies.

Pathophysiology

Ovarian aging is characterized by accelerated follicular atresia, reduced stem cell activity, mitochondrial dysfunction, increased oxidative stress, and altered intra-ovarian signaling pathways such as PI3K/AKT and Hippo. In POI, autoimmune, genetic, and iatrogenic factors contribute to premature follicular depletion or dysfunction. The central pathology involves both the quantitative depletion of primordial follicles and qualitative impairment of the ovarian microenvironment, resulting in hypoestrogenism and infertility.

Risk Factors

Risk factors for ovarian insufficiency include advanced maternal age, family history of POI, genetic syndromes (e.g., Turner syndrome, FMR1 premutation), autoimmune disorders, exposure to gonadotoxins (chemotherapy, radiation), pelvic surgery, and environmental toxins. Lifestyle factors such as smoking and low body mass index have also been implicated in accelerating ovarian senescence.

Clinical Features

Women with DOR or POI commonly present with menstrual irregularities, oligomenorrhea or amenorrhea, infertility, vasomotor symptoms, and signs of hypoestrogenism. Biochemically, elevated follicle-stimulating hormone (FSH), low anti-Müllerian hormone (AMH), and reduced estradiol levels are typical findings. The spectrum of presentation can range from subtle menstrual changes to abrupt cessation of menses in young women.

Diagnosis

Diagnosis involves a thorough clinical evaluation, including menstrual history, reproductive age, and risk factor assessment. Laboratory markers such as FSH, AMH, and antral follicle count (AFC) via transvaginal ultrasound are central to assessing ovarian reserve. Genetic testing for FMR1 premutation or karyotype analysis may be indicated in selected cases. POI is diagnosed by amenorrhea for at least four months and two elevated FSH values (>40 IU/L) at least one month apart in women <40 years old.

Treatment & Management

Conventional management for DOR and POI includes hormone replacement therapy (HRT) to mitigate hypoestrogenic symptoms, and assisted reproductive technologies (ART) such as in vitro fertilization (IVF) with autologous or donor oocytes. For women desiring fertility, donor egg IVF remains the most successful option, although patient acceptance varies. Adjunctive measures, including lifestyle optimization and management of comorbidities, are essential for holistic care.

Recent Advances / Emerging Therapies

The advent of ovarian rejuvenation therapies marks a paradigm shift. Intraovarian injection of autologous PRP has demonstrated potential in improving ovarian response and resumption of menses in small case series, attributed to growth factor-mediated neovascularization and follicular activation. Mesenchymal stem cell transplantation, utilizing sources such as bone marrow or adipose tissue, has been shown in early-phase trials to enhance ovarian function, likely via paracrine effects and microenvironmental modulation. Molecular pathway interventions, notably disruption of Hippo signaling through ovarian tissue fragmentation, have yielded preliminary success in activating residual primordial follicles (in vitro activation, IVA). However, robust randomized controlled trials are lacking and optimal protocols remain to be standardized. Safety, long-term outcomes, and oncological risks require vigilant assessment.

Guideline Recommendations

Current guidelines from reproductive societies remain conservative, recommending that ovarian rejuvenation therapies be offered only within the context of clinical trials or experimental protocols. The American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) emphasize informed consent, clear communication of experimental status, and long-term follow-up as pivotal. Clinicians are advised to counsel patients regarding the limited evidence base, potential risks, and alternative options with established efficacy.

Conclusion

Ovarian rejuvenation therapies constitute an exciting but still investigational area in reproductive medicine. While early evidence suggests potential for restoring ovarian function and fertility in selected women, the lack of high-quality data precludes routine clinical use. Ongoing research is critical to elucidate mechanisms, optimize protocols, and establish safety. Multidisciplinary collaboration and patient-centered counseling remain essential as the field evolves toward personalized, mechanism-driven reproductive care.